胆固醇白质通路的完整性在预发性和早期显现的利维体疾病中
Tamir Eisenstein1,2, Karolien Groenewald1,2, Ludo van Hillegondsberg2
1Oxford Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical Neurosciences, University of Oxford, Headley Way, Headington, Oxford OX3 9DU, UK.
Brain communications
|November 20, 2025
概括
梅纳特基底核 (NbM) 的白物质通路显示出可能成为勒维体疾病的生物标志物. 完整的途径与更好的认知和较低的转化风险相关,在早期的疾病阶段.
科学领域:
- 神经科学是一个神经科学.
- 神经成像是一种神经成像.
- 神经学 神经学
背景情况:
- 梅纳特基底核 (NbM) 的退化,这是一个关键的胆固醇中心,与高级的勒维体 (LB) 疾病有关.
- 虽然连接NbM与皮质的白质通道在LB痴呆中受到影响,但它们在前期阶段的作用不太清楚.
- 调查NbM通路的完整性对于了解早期疾病机制和进展至关重要.
研究的目的:
- 为了检查NbM白质道的微观结构完整性,在prodromal (孤立的快速眼动睡眠行为障碍 - iRBD) 和早期显现 (帕金森病 - PD) LB疾病中.
- 评估NbM通路完整性与认知功能,疾病进展和表转化风险之间的关系.
- 通过将连接性与皮层缩相关联,探索NbM作为潜在疾病中心的作用.
主要方法:
- 扩散MRI (dMRI) 用于分析白质微结构完整性,用于患者iRBD (n=67),PD (n=73) 和健康对照 (n=53).
- 研究了途径完整性,认知表现 (口语流,MoCA) 和表态转换风险之间的关联.
- NbM的皮质结构连接性与疾病特异性皮质缩模式空间相关.
主要成果:
- 较高的基线微观结构完整性NbM横向和中间途径与更好的口语流性相关.
- 更大的中介通路完整性与随着时间的推移缓慢的MoCA下降有关.
- 在基线完整的NbM通路降低了iRBD患者未来的转换风险.
- 在iRBD中,NbM连接与较低的灰质体积相关,但不是PD,这表明在iRBD皮层病理学中发挥了作用.
- 在基线患者组和对照组之间没有发现NbM通路完整性的显著差异.
结论:
- 在iRBD中,NbM白质路径可以作为临床转化风险和皮质病理的非侵入性生物标志物.
- 这些途径是iRBD和早期PD基线和纵向认知功能的潜在指标.
- NbM通路的完整性可以帮助分层患者进行针对疾病修饰和神经保护疗法的临床试验.
相关概念视频
Neural Regulation
43.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


